Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis
- PMID: 6335067
Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis
Abstract
Eight adult patients without peritonitis maintained on chronic ambulatory peritoneal dialysis (CAPD) were administered a single oral dose of 320 mg trimethoprim (TMP) and 1600 mg sulfamethoxazole (SMX) to characterize the pharmacokinetics of TMP and SMX. Ten blood samples were drawn following the dose. TMP and SMX-active (SMXA) concentrations were quantified in serum and dialysate. The half-life of TMP and SMXA determined by model independent methods were 33.7 +/- 10.5 h (mean +/- SD) and 13.8 +/- 2.2 h respectively. Total body clearance of TMP was 32.8 +/- 10.1 ml/min and SMXA was 21.9 +/- 6.4 ml/min. CAPD clearance of TMP was 2.27 +/- 0.81 ml/min and SMXA was 1.72 +/- 0.93 ml/min. The average peritoneal dialysate concentrations over the 72-hour collection period of TMP and SMXA were 0.9 +/- 0.1 mg/l and 5.3 +/- 0.8 mg/l respectively. A dose of 320 mg TMP and 1600 mg SMX every 48 hours is recommended for CAPD patients with mild to moderate systemic infections.
Similar articles
-
Pharmacokinetics of cefradine, sulfamethoxazole and trimethoprim and their metabolites in a patient with peritonitis undergoing continuous ambulatory peritoneal dialysis.Pharm Weekbl Sci. 1987 Apr 24;9(2):110-6. doi: 10.1007/BF01960745. Pharm Weekbl Sci. 1987. PMID: 3495778
-
Pharmacokinetics and body fluid and endometrial concentrations of trimethoprim-sulfamethoxazole in mares.Am J Vet Res. 1988 Jun;49(6):918-22. Am J Vet Res. 1988. PMID: 3261143
-
[Comparison of pharmacokinetics of the combination trimethoprim and sulfamethoxazole in patients with liver diseases and healthy persons].Arzneimittelforschung. 1975 Apr;25(4):656-66. Arzneimittelforschung. 1975. PMID: 1174084 German.
-
[Clinical pharmacology of co-trimoxazole (biseptol)].Postepy Hig Med Dosw. 1983 Sep-Dec;37(5-6):537-60. Postepy Hig Med Dosw. 1983. PMID: 6387682 Review. Polish. No abstract available.
-
Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus.Pharmacotherapy. 2005 Feb;25(2):253-64. doi: 10.1592/phco.25.2.253.56956. Pharmacotherapy. 2005. PMID: 15767239 Review.
Cited by
-
Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.Clin Pharmacokinet. 1990 Feb;18(2):104-17. doi: 10.2165/00003088-199018020-00002. Clin Pharmacokinet. 1990. PMID: 2180611 Review.
-
Pharmacokinetics of cefradine, sulfamethoxazole and trimethoprim and their metabolites in a patient with peritonitis undergoing continuous ambulatory peritoneal dialysis.Pharm Weekbl Sci. 1987 Apr 24;9(2):110-6. doi: 10.1007/BF01960745. Pharm Weekbl Sci. 1987. PMID: 3495778
-
[Treatment of peritonitis during continuous ambulatory peritoneal dialysis (CAPD) with co-trimoxazole, cefazolin or vancomycin].Klin Wochenschr. 1987 Jul 15;65(12):562-70. doi: 10.1007/BF01727623. Klin Wochenschr. 1987. PMID: 3498086 German.
-
Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.Clin Pharmacokinet. 1988 Sep;15(3):133-64. doi: 10.2165/00003088-198815030-00001. Clin Pharmacokinet. 1988. PMID: 3052984 Review.
-
Co-trimoxazole (sulphamethoxazole plus trimethoprim) peritoneal barrier transfer pharmacokinetics.Clin Pharmacokinet. 1989 May;16(5):317-25. doi: 10.2165/00003088-198916050-00004. Clin Pharmacokinet. 1989. PMID: 2787223